Skip to main content

Advertisement

Table 3 Distribution of primary and secondary study endpoints as well as preservation solutions to the different eras, 580 patients from the Kiel liver transplant program

From: Comparable outcome of liver transplantation with Histidine-Tryptophan-Ketoglutarate vs. University of Wisconsin preservation solution: a retrospective observational double-center trial

  Era
I II III IV p-value
n (%) 9 (1.6%) 96 (16.6%) 152 (26.2%) 323 (55.7%) n.a.
HTK 0 (0%) 8 (8.3%) 68 (44.7%) 281 (87.0%) <0.0011
UW 9 (100.0%) 88 (91.7%) 84 (55.3%) 42 (13%) <0.0011
3 months mortality 3 (33.3%) 22 (22.9%) 35 (23.0%) 32 (9.9%) <0.0011
graft loss 8 (88.9%) 59 (61.5%) 75 (49.7%) 85 (26.5%) <0.0011
3 month graft survival 6 (66.7%) 68 (70.8%) 106 (69.7%) 262 (81.1%) 0.0211
Biliary complications 1 (11.1%) 33 (34.4%) 47 (30.9%) 18 (19.4%) 0.0991
  1. HTK = Histidine-Tryptophane-Ketoglutarate solution; UW = University of Wisconsin solution; SD = Standard Deviation.
  2. 1Pearson’s Chi2 Test.